Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECLAIIM study of subcutaneous Hizentra in adults with dermatomyositis
NL-OMON55228Phase 3Withdrawn
- Sponsor
- CSL Behring
- Start
- Aug 2019
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of polyvalent human immunoglobulin in dermatomyositis (DM) (2 arms), sponsored by CSL Behring. Primary endpoint: Responder status based on Total Improvement Score. Planned start Aug 2019; status: withdrawn.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NL-OMON55228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55228.